(Q34693969)

English

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

Berit Maria Müller

1

object named as

Berit Maria Müller

0 references

9

object named as

Wilko Weichert

0 references

8

object named as

Manfred Dietel

1 reference

Europe PubMed Central

4 August 2017

author name string

Lisa Jana

2

1 reference

Europe PubMed Central

4 August 2017

Atsuko Kasajima

3

1 reference

Europe PubMed Central

4 August 2017

Annika Lehmann

4

1 reference

Europe PubMed Central

4 August 2017

Judith Prinzler

5

1 reference

Europe PubMed Central

4 August 2017

Jan Budczies

6

1 reference

Europe PubMed Central

4 August 2017

Klaus-Jürgen Winzer

7

1 reference

Europe PubMed Central

4 August 2017

Carsten Denkert

10

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

30 April 2013

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

13

1 reference

Europe PubMed Central

4 August 2017

215

1 reference

Europe PubMed Central

4 August 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-13-215

0 references

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Pharmacogenetics of endocrine therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Epigenetics and cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

HDAC expression and clinical prognosis in human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Histone deacetylases and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Epigenetic therapy of cancer: past, present and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Resistance to endocrine therapy in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Histone deacetylases (HDACs): characterization of the classical HDAC family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

7 July 2018

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-215

21 January 2018

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-215

21 January 2018

Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646665

26 October 2018

Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/23627572

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-13-215

1 reference

Europe PubMed Central

4 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34693969&oldid=1559781178"